LightNews LightNews
msolly.bsky.social
@msolly.bsky.social
95 followers 14 following 87 posts
Posts Replies Media Videos
msolly.bsky.social
$BNTC $CVAC BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer

Each share of CureVac will be exchanged for approx. $5.46 in BioNTech American Depositary Shares

investors.biontech.de/news-release...
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer | BioNTech
Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in the execution of its ...
investors.biontech.de
June 12, 2025 at 10:57 AM
msolly.bsky.social
$TRML Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease

www.globenewswire.com/news-release...
Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Dis...
– Rapid, deep, and durable reductions in high-sensitivity C-reactive protein (hs-CRP) through Day 90 achieved across all pacibekitug arms with high...
www.globenewswire.com
May 20, 2025 at 11:33 AM
msolly.bsky.social
$CYTK Cytokinetics Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy

DEC 26, 2025

www.globenewswire.com/news-release...
Cytokinetics Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy
SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug...
www.globenewswire.com
May 1, 2025 at 8:18 PM
msolly.bsky.social
$RHHBY Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the United States over the next five years

www.roche.com/investors/up...
Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the United States over the next five years
USD 50 billion commitment includes new state-of-the art research and development (R&D) sites, new and expanded manufacturing facilities in Indiana, Pennsylvania, Massachusetts and California and...
www.roche.com
April 22, 2025 at 5:15 AM
msolly.bsky.social
$VERV Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

www.globenewswire.com/news-release...
Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69%...
www.globenewswire.com
April 14, 2025 at 11:03 AM
msolly.bsky.social
$SLNO Soleno Therapeutics Announces VYKAT(TM) XR Launch

First prescriptions delivered to individuals with PWS

www.globenewswire.com/news-release...
Soleno Therapeutics Announces VYKAT(TM) XR Launch
First prescriptions delivered to individuals with PWS...
www.globenewswire.com
April 14, 2025 at 11:02 AM
msolly.bsky.social
$IRWD Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide

FDA interaction indicates that a confirmatory Phase 3 trial evaluating apraglutide in SBS-IF is needed

Co exploring strategic alternatives

www.businesswire.com/news/home/20...
Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastroin...
www.businesswire.com
April 14, 2025 at 11:02 AM
msolly.bsky.social
$THRD Third Harmonic Bio Announces Plan of Liquidation and Dissolution

Initial distribution expected in the range between approximately $246.6 million and $255.4 million, or approximately $5.13 and $5.33 per share of common stock

www.globenewswire.com/news-release...
Third Harmonic Bio Announces Plan of Liquidation and Dissolution
Board of Directors has approved plan to liquidate and intends to seek stockholder approval for dissolution of the Company at the Annual Meeting of...
www.globenewswire.com
April 14, 2025 at 10:52 AM
msolly.bsky.social
$PFE Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron

Discontinue development of danuglipron (PF-06882961)

www.businesswire.com/news/home/20...
Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron
Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) recepto...
www.businesswire.com
April 14, 2025 at 10:49 AM
msolly.bsky.social
$RYTM Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity

www.globenewswire.com/news-release...
Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity
-- Patients with acquired hypothalamic obesity on setmelanotide therapy (n=81) achieved mean BMI change of -16.5% compared with +3.3% for placebo (n=39) at...
www.globenewswire.com
April 7, 2025 at 11:02 AM
msolly.bsky.social
$SGMO Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

$18m upfront

www.businesswire.com/news/home/20...
Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System
SANGAMO THERAPEUTICS ANNOUNCES CAPSID LICENSE AGREEMENT WITH LILLY TO DELIVER GENOMIC MEDICINES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM
www.businesswire.com
April 3, 2025 at 8:03 PM
msolly.bsky.social
$MLTX MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

ir.moonlaketx.com/news-release...
MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates | MoonLake Immunotherapeuti...
Agreement with Hercules Capital significantly increases financial and operational strength, provides up to $500 million in capital with no dilution to shareholders, an attractive cost of capital and l...
ir.moonlaketx.com
April 3, 2025 at 11:03 AM
msolly.bsky.social
$NRIX Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

Target different from STAT6

www.globenewswire.com/news-release...
Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases
The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 program Nurix DEL-AI drug discovery...
www.globenewswire.com
April 2, 2025 at 11:04 AM
msolly.bsky.social
(1/2) Well surely 2Q25 can't be worse than this, right? Here are some catalysts for 2Q25. Some that I'm watching are highlighted in peach!

Let me know if I missed your favorite

$APGE $CDTX $CELC $CRVS $KALA $KYMR $LLY $NKTR $RCKT $RYTM $RZLT $SRRK $TRML $VERA $VERV $VIGL
April 1, 2025 at 11:10 AM
Reposted
matthewherper.bsky.social
Our story on Marks’s ouster has been updated with a lot of comment and context www.statnews.com/2025/03/28/f...
Peter Marks, FDA’s top vaccine regulator, forced out
Top FDA official Peter Marks was forced to resign as the director of the Center for Biologics Evaluation and Research.
www.statnews.com
March 29, 2025 at 2:56 AM
msolly.bsky.social
$OPT Opthea Announces COAST Phase 3 Trial Topline Results

Fail

www.globenewswire.com/news-release...
Opthea Announces COAST Phase 3 Trial Topline Results
COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial...
www.globenewswire.com
March 24, 2025 at 5:02 AM
msolly.bsky.social
$SKYE Moving up the obesity readout from 4Q25 -> Late 3Q/4Q25 due to faster-than-expected enrollment. No more interim, which was originally 2Q25

www.globenewswire.com/news-release...
Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Enrollment completed in Phase 2a CBeyond™ trial of CB1 inhibitor, nimacimab, in obesity and overweightFaster-than-expected enrollment enables full top-line...
www.globenewswire.com
March 20, 2025 at 8:05 PM
msolly.bsky.social
$SNY Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline

$600 million upfront and potential future payments totaling $1.3 billion

www.globenewswire.com/news-release...
Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter...
www.globenewswire.com
March 20, 2025 at 11:00 AM
msolly.bsky.social
$IMVT Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

www.globenewswire.com/news-release...
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose...
www.globenewswire.com
March 19, 2025 at 11:46 AM
msolly.bsky.social
$BDTX Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

Black Diamond will receive an upfront payment of $70 million and up to $710 million in milestones

www.globenewswire.com/news-release...
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
The partnership underscores Servier’s commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and...
www.globenewswire.com
March 19, 2025 at 11:03 AM
msolly.bsky.social
$ZEAL $RHHBY Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide for obesity

Zealand will receive upfront cash payments of $1.65B, and milestones for a total consideration of up to $5.3B

www.globenewswire.com/news-release...
Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity
Company announcement – No. 4 / 2025 Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as...
www.globenewswire.com
March 12, 2025 at 7:14 AM
msolly.bsky.social
$IONS Ionis and Ono announce global license agreement for sapablursen in polycythemia vera

www.businesswire.com/news/home/20...
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a license a
www.businesswire.com
March 11, 2025 at 10:18 PM
msolly.bsky.social
$TSVT 2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb

$5.00 per share, all-cash transaction

www.businesswire.com/news/home/20...
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb
2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) (“BMS”) will acquire all
www.businesswire.com
March 11, 2025 at 2:24 AM
msolly.bsky.social
$PTGX Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis

feeds.issuerdirect.com/news-release...
feeds.issuerdirect.com
March 10, 2025 at 1:51 PM
msolly.bsky.social
$MLYS Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

www.globenewswire.com/news-release...
Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension
– Launch-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a 16.9 mmHg reduction in systolic blood pressure, and a 9.1 mmHg...
www.globenewswire.com
March 10, 2025 at 11:11 AM